$SAVA
CASSAVA SCIENCES INC

2021 Q3 Form 10-Q Financial Statement

#000106953021000045 Filed on August 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.712M $1.237M $820.0K
YoY Change 64.62% 50.85% -3.53%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $212.0K $8.000K $0.00
YoY Change
% of Gross Profit
Operating Expenses $9.753M $5.138M $1.163M
YoY Change 578.71% 341.79% 0.87%
Operating Profit -$9.753M -$5.138M -$1.163M
YoY Change 578.71% 341.79% 0.87%
Interest Expense $15.00K $13.00K $30.00K
YoY Change 50.0% -56.67% -66.67%
% of Operating Profit
Other Income/Expense, Net $176.0K
YoY Change
Pretax Income -$9.562M -$5.125M -$1.140M
YoY Change 568.67% 349.56% 7.55%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.562M -$5.125M -$1.136M
YoY Change 568.67% 351.14% 7.27%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$239.3K -$128.3K -$46.00K
COMMON SHARES
Basic Shares Outstanding 40.01M 24.78M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $241.5M $278.3M $25.30M
YoY Change 902.17% 999.82% 36.76%
Cash & Equivalents $241.5M $278.3M $25.25M
Short-Term Investments
Other Short-Term Assets $10.39M $1.304M $186.0K
YoY Change 942.23% 601.08% 279.59%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $251.9M $279.6M $25.44M
YoY Change 904.81% 998.89% 36.9%
LONG-TERM ASSETS
Property, Plant & Equipment $20.70M $75.00K $13.00K
YoY Change 172358.33% 476.92% -82.67%
Goodwill
YoY Change
Intangibles $1.209M
YoY Change
Long-Term Investments
YoY Change
Other Assets $199.0K $1.420M
YoY Change
Total Long-Term Assets $22.33M $1.747M $58.00K
YoY Change 6709.15% 2912.07% -73.87%
TOTAL ASSETS
Total Short-Term Assets $251.9M $279.6M $25.44M
Total Long-Term Assets $22.33M $1.747M $58.00K
Total Assets $274.2M $281.3M $25.50M
YoY Change 979.76% 1003.24% 35.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.345M $1.912M $416.0K
YoY Change 404.3% 359.62% -29.97%
Accrued Expenses $3.251M $2.462M $755.0K
YoY Change 482.62% 226.09% 321.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.326M $4.637M $1.314M
YoY Change 441.61% 252.89% 40.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $194.0K $188.0K
YoY Change -35.33%
Total Long-Term Liabilities $194.0K $188.0K $0.00
YoY Change -35.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.326M $4.637M $1.314M
Total Long-Term Liabilities $194.0K $188.0K $0.00
Total Liabilities $6.684M $4.825M $1.314M
YoY Change 368.72% 267.2% 33.81%
SHAREHOLDERS EQUITY
Retained Earnings -$193.1M -$183.6M -$170.9M
YoY Change 12.07% 7.45% 2.7%
Common Stock $40.00K $40.00K $25.00K
YoY Change 53.85% 60.0% 47.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $267.6M $276.5M $24.18M
YoY Change
Total Liabilities & Shareholders Equity $274.2M $281.3M $25.50M
YoY Change 979.76% 1003.24% 35.59%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$9.562M -$5.125M -$1.136M
YoY Change 568.67% 351.14% 7.27%
Depreciation, Depletion And Amortization $212.0K $8.000K $0.00
YoY Change
Cash From Operating Activities -$14.76M -$5.145M -$800.0K
YoY Change 571.09% 543.13% 33.33%
INVESTING ACTIVITIES
Capital Expenditures -$22.04M -$73.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $300.0K
YoY Change
Cash From Investing Activities -$22.04M -$73.00K $300.0K
YoY Change -124.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.00K 1.266M 200.0K
YoY Change -92.5% 533.0%
NET CHANGE
Cash From Operating Activities -14.76M -5.145M -800.0K
Cash From Investing Activities -22.04M -73.00K 300.0K
Cash From Financing Activities 75.00K 1.266M 200.0K
Net Change In Cash -36.73M -3.952M -300.0K
YoY Change 2960.83% 1217.33% -50.0%
FREE CASH FLOW
Cash From Operating Activities -$14.76M -$5.145M -$800.0K
Capital Expenditures -$22.04M -$73.00K $0.00
Free Cash Flow $7.277M -$5.072M -$800.0K
YoY Change 534.0% 33.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001069530
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q2 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
278254000
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40014695
CY2021Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2021Q2 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2021Q2 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-29959
dei Entity Registrant Name
EntityRegistrantName
Cassava Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1911336
dei Entity Address Address Line1
EntityAddressAddressLine1
7801 N. Capital of Texas Highway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78731
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
501-2444
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
SAVA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93506000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1304000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
488000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
279558000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
93994000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
252000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
295000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1420000
CY2021Q2 us-gaap Assets
Assets
281305000
CY2020Q4 us-gaap Assets
Assets
94300000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1912000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
911000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2462000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
719000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
120000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
83000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
93000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
50000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
94000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4637000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1865000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
188000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
235000
CY2021Q2 us-gaap Liabilities
Liabilities
4825000
CY2020Q4 us-gaap Liabilities
Liabilities
2100000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40011894
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40011894
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35237987
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35237987
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
40000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
460012000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
267086000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183572000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174921000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
276480000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
92200000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281305000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94300000
CY2021Q2 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
3901000
CY2020Q2 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
591000
sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
6430000
sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
1135000
CY2020Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
246000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
346000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5138000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
1163000
us-gaap Operating Expenses
OperatingExpenses
8671000
us-gaap Operating Expenses
OperatingExpenses
2385000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1237000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
818000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2241000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1596000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5138000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1163000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8671000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2385000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
13000
CY2020Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
27000
us-gaap Interest And Other Income
InterestAndOtherIncome
20000
us-gaap Interest And Other Income
InterestAndOtherIncome
99000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5125000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1136000
us-gaap Net Income Loss
NetIncomeLoss
-8651000
us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39953000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24779000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38843000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24630000
us-gaap Net Income Loss
NetIncomeLoss
-8651000
us-gaap Net Income Loss
NetIncomeLoss
-2286000
us-gaap Share Based Compensation
ShareBasedCompensation
665000
us-gaap Share Based Compensation
ShareBasedCompensation
522000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
346000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2236000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-82000
sava Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-31000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1001000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-37000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1743000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-22000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
360000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
37000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
26000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-44000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7445000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2036000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
360000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1749000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
692000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3849000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189825000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
192266000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3849000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
184748000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2173000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93506000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23081000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
278254000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25254000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183600000
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company makes estimates and assumptions in preparing its condensed financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and assumptions.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2021Q2 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
900000
CY2020Q2 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1100000
sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1500000
sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
2400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5125000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1136000
us-gaap Net Income Loss
NetIncomeLoss
-8651000
us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39953000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24779000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38843000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24630000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1136000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24919333
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24184000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35237987
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
92200000
CY2021Q1 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
554019
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
457000
CY2021Q2 us-gaap Deposit Contracts Assets
DepositContractsAssets
1166000
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
138000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
31000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1304000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
488000
CY2021Q2 sava Deposit Contracts Assets Noncurrent
DepositContractsAssetsNoncurrent
1420000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1420000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21841810
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
22099000
CY2020Q1 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
2888092
CY2020Q1 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
3613000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1150000
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24729902
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24832000
CY2020Q2 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
189431
CY2020Q2 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
236000
CY2021Q1 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
692000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
135015
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1746000
CY2021Q1 us-gaap Shares Issued
SharesIssued
4081633
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189825000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3526000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40008654
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
281187000
CY2021Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3240
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5125000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40011894
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
276480000
sava Stock Option And Performance Award Activity
StockOptionAndPerformanceAwardActivity
<div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.38in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><span style="white-space:pre-wrap; "/><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Performance Awards</span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,817,504</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">138,055</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">85,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-7387b2f8-3541-4023-9756-82adc732f803;">—</span></span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">234,994</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-2f0e06e9-48f5-425a-b7bf-f3e6d12bb01b;">—</span></span></p></td></tr><tr style="height: 0.17in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,338</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b6689b79-c3e5-48d6-b220-ee6f5bc5daa6;">—</span></span></p></td></tr><tr style="height: 0.17in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of June 30, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,658,172</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">138,055</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.08in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div>
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
415000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
252000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
665000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
522000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
27000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
25000
us-gaap Operating Lease Payments
OperatingLeasePayments
27000
us-gaap Operating Lease Payments
OperatingLeasePayments
50000
CY2021Q2 us-gaap Other Commitment
OtherCommitment
1900000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
892000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
878000
CY2020Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
246000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
346000
CY2020Q2 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
260000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
360000

Files In Submission

Name View Source Status
0001069530-21-000045-index-headers.html Edgar Link pending
0001069530-21-000045-index.html Edgar Link pending
0001069530-21-000045.txt Edgar Link pending
0001069530-21-000045-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sava-20210630.xsd Edgar Link pending
sava-20210630x10q.htm Edgar Link pending
sava-20210630x10qg001.jpg Edgar Link pending
sava-20210630x10qg002.jpg Edgar Link pending
sava-20210630x10qg003.jpg Edgar Link pending
sava-20210630x10qg004.jpg Edgar Link pending
sava-20210630x10qg005.jpg Edgar Link pending
sava-20210630x10q_htm.xml Edgar Link completed
sava-20210630xex10_3.htm Edgar Link pending
sava-20210630xex31_1.htm Edgar Link pending
sava-20210630xex31_2.htm Edgar Link pending
sava-20210630xex32_1.htm Edgar Link pending
sava-20210630_cal.xml Edgar Link unprocessable
sava-20210630_def.xml Edgar Link unprocessable
sava-20210630_lab.xml Edgar Link unprocessable
sava-20210630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending